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Purpose: To determine the outcomes of Ahmed glaucoma valve (AGV) and transscleral diode
cyclophotocoagulation (CPC) in neovascular glaucoma (NVG). Methods: This was a single‑center
retrospective comparative case series involving chart review of consecutive patients who underwent AGV or
CPC for treatment of NVG and had ≥6 months of follow‑up. Surgical failure at 6 months, defined as an IOP
of >21 or <6 mm Hg with hypotony maculopathy after 1 month, progression to no light perception (NLP)
vision, glaucoma reoperation, or removal of AGV were the main outcome measures. Results: In total, 121
eyes of 121 patients were included (70 AGV and 51 CPC). Baseline demographics, visual acuity (VA), and
intraocular pressure (IOP) were comparable between groups. At 6 months, failure was significantly higher
in the CPC group than in the AGV group (43.1% vs. 17.1%, P = 0.020). Both groups had similar IOP and
medication number at 6 months, but VA was significantly lower in the CPC group compared to the AGV
group (2.4 ± 0.8 vs. 1.9 ± 1.0, P = 0.017). More CPC eyes required reoperation for glaucoma than AGV
eyes (11.8% vs. 1.4%, P = 0.041). Multivariate regression analysis identified higher preoperative IOP (P = 0.001)
and CPC surgery (P = 0.004) as independent predictors of surgical failure at 6 months. Age, sex, race, NVG
etiology, bilaterality of the underlying retinal pathology, perioperative retina treatment, and prior or combined
vitrectomy were not significant. Conclusion: AGV and CPC had comparable IOP and medication reduction
in NVG eyes at 6 months. CPC was more frequently associated with failure, reoperation for glaucoma, and
worse visual outcomes. High preoperative IOP and CPC surgery independently predicted surgical failure.
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Neovascular glaucoma (NVG) is associated with poor visual
prognosis despite treatment.[1,2] The most common causes of
NVG are proliferative diabetic retinopathy, ischemic central
retinal vein occlusion, and ocular ischemic syndrome.[3] Retinal
hypoxia stimulates the release of inflammatory cytokines,
promoting fibrosis and neovascularization of the iris and
anterior segment,[4] which is associated with fibrovascular
membrane formation, leading to secondary angle closure and
intraocular pressure (IOP) elevation.[5]
Management of NVG is difficult as trabeculectomy is
associated with a high proportion of failure.[6,7] Tube shunts,
including Ahmed glaucoma valve (AGV) or Baerveldt
glaucoma implant, are the standard of care for IOP‑lowering
in NVG.[8,9] Transscleral cyclophotocoagulation (CPC) has also
been investigated as a possible management strategy with
variable success and possibly worse outcomes compared to
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tube shunt surgery.[10‑12] CPC has potential advantages as it may
allow patients to avoid incisional surgery, can be performed
in a lower‑resource setting, and is a relatively short procedure.
Limited studies have reported CPC outcomes in NVG[10] or
compared CPC with tube shunt surgery.[11,12] The present study
aims to compare the outcomes of AGV surgery and CPC in the
setting of NVG in the early postoperative period.

Methods
Study design
This was a single‑center, retrospective comparative case series.
The study was approved by the institute’s review board and
was in accordance with Health Insurance Portability and
Accountability Act regulations. As this was a retrospective study
with de‑identified data, informed consent was not required.
The medical records of consecutive patients diagnosed with
NVG who were treated with the AGV (New World Medical
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Inc., Rancho Cucamonga, CA, USA) or CPC between 2007 and
2019 at a tertiary eye care hospital were reviewed. Surgeries
were performed by seven glaucoma surgeons (J. S. M., M. R.
M., R. R., D. L., N. N. K., L. J. K., and A. G. S.). All surgeons
were fellowship‑trained glaucoma specialists, and a resident
or fellow assisted in all cases. The diagnosis of NVG was based
on the presence of neovascularization of the iris and/or anterior
chamber angle and IOP > 21 mm Hg.
Inclusion and exclusion criteria
Patients aged ≥18 years with refractory NVG and preoperative
IOP >21 mm Hg were included. Exclusion criteria included
no light perception (NLP) vision at baseline and a follow‑up
duration of <6 months. In patients who underwent multiple
glaucoma operations, only the first tube shunt or the first
CPC were included. Both continuous wave (CW) and
micropulse (MP) CPC were included.
Patient visits
Visits at baseline, postoperative day 1, week 1, and months
1, 3, and 6 were reviewed from the electronic medical record.
Demographic data such as age, sex, and race as well as medical
and surgical history were collected. Preoperative clinical data
included visual acuity (VA), IOP, topical glaucoma medications,
synechial angle closure, and presence of hyphema. Details
of neovascular disease, including laterality, NVG etiology,
bilaterality of the underlying retinal pathology, retinal
treatment in the form of panretinal photocoagulation (PRP)
or intravitreal injection of anti‑vascular endothelial growth
factor (VEGF) within 2 weeks of surgery, and prior or
concomitant vitrectomy, were identified. Postoperative data
included VA, IOP, glaucoma medications, postoperative
complications, and need for additional glaucoma surgery.
Outcome measures
The primary outcome measure was surgical failure at 6 months,
defined as IOP >21 mm Hg with medications or <5 mm Hg at
two consecutive visits after 1 month, progression to NLP vision,
glaucoma reoperation (CPC or tube shunt), or removal of AGV.
Eyes that failed due to IOP <5 mm Hg had to exhibit clinically
significant signs of hypotony after 1 month postoperatively.
Changes in VA, IOP, and glaucoma medications at 6 months
were secondary outcome measures. Eyes that met the failure
criteria due to reoperation for glaucoma or removal of the
implant at any time point were censored from the analysis of
subsequent visits. Predictive factors for surgical failure and
rate of surgical complications were also identified.
Statistical analysis
Statistical analyses were performed using SPSS software
version 27.0 (IBM Analytics, Chicago, IL, USA). Snellen VA
measurements were converted to logarithm of the minimum
angle of resolution (logMAR) VA equivalents for the purpose
of data analysis. Continuous variables were presented as
mean ± standard deviation. Proportions (%) were used to
describe categorical variables. Two‑sided Student t‑tests and
Chi‑square tests were used to compare treatment groups for
continuous and categorical variables, respectively. Analysis
of covariance was performed for between‑group comparisons
at 6 months after adjusting for baseline characteristics. Paired
sample t tests and McNemar test were used to compare
continuous and categorical variables within the same group,
respectively. P < 0.05 was considered significant. Kaplan–Meier
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survival analysis with log‑rank tests was used to report the
cumulative rate of surgical failure in the AGV versus CPC
eyes. Cox regression analysis was performed to identify
factors predictive of surgical failure. Variables in the univariate
analysis with P < 0.05 were entered into the multivariate model
by using the forward stepwise Wald method. We estimated
sample size (80% power and an alpha of 0.05) by considering
prior outcomes from a prospective randomized study that did
not detect a significant difference in surgical failure between
33 AGV eyes and 33 CPC eyes with NVG.[11]

Results
Baseline characteristics
Of the 121 eyes of 121 patients included, 70 eyes underwent AGV
and 51 eyes underwent CPC. Baseline patient characteristics
are displayed in Table 1. Mean age, sex, race, underlying NVG
etiology, and baseline VA, IOP, medication number, synechial
angle closure, and presence of hyphema were comparable in
both groups. Proliferative diabetic retinopathy (48.8%) and
retinal vein occlusion (31.4%) were the most prevalent etiologies
of NVG in both groups. Type of perioperative retinal treatment
differed between groups. While more AGV eyes received PRP or
intravitreal anti‑VEGF injection (74.3% and 77.1%, respectively)
within 2 weeks of surgery as compared to 11.8% and 31.4% in the
CPC group (P < 0.001 for both), pars plana vitrectomy was more
commonly combined in the CPC group (27.5%) as compared to
the AGV group (4.3%) (P < 0.001). For the AGV group (N = 70),
implants were placed in the superotemporal quadrant and the
tubes were inserted into the anterior chamber in 67 (95.7%)
eyes. Pars plana vitrectomy was performed concomitantly
with pars plana AGV placement in the superonasal quadrant
in three (4.3%) eyes. For the CPC group (N = 51), CW‑CPC was
performed in 25 (49%) eyes with a mean power of 1983 mW at
an average duration of 2.6 s with application of 12–30 spots, and
MP‑CPC was performed in 26 (51%) eyes with a mean power
of 2025 mW at an average duration of 220 s.
Month 6 outcomes
Clinical outcomes at 6 months are displayed in Table 2.
Surgical failure
At 6 months, a total of 34 eyes (28.1%) met failure criteria, with a
significantly higher failure rate in the CPC group (22 eyes or 43.1%)
compared to the AGV group (12 eyes or 17.1%) (P = 0.020). When
excluding CPC eyes that failed due to CPC repeat only, the
difference remained significant, with a total of 31 eyes (25.6%)
meeting failure criteria, with a significantly higher failure rate
in the CPC group (19 eyes or 37.3%) compared to the AGV
group (12 eyes or 17.1%) (P = 0.020). Kaplan–Meier survival
analysis showed that the cumulative proportion of surgical
failure over 6 months was significantly higher in the CPC group
as compared to the AGV group (P = 0.002) [Fig. 1]. A difference
in surgical failure between the CW‑CPC and MP‑CPC (P = 0.57)
groups was not detected. Cox regression analysis was performed
to identify the predictive factors of surgical failure at 6 months.
Based on the findings from the univariate analysis, a multivariate
model (P < 0.001) was created and identified higher preoperative
IOP (P = 0.001) and surgery type as CPC (P = 0.004) as the strongest
predictors of surgical failure [Table 3]. Age, sex, race, NVG etiology,
bilaterality of the underlying retinal pathology, perioperative PRP
or intravitreal anti‑VEGF, and prior or combined vitrectomy were
not significant predictors of surgical failure.
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Table 1: Baseline patient characteristics of the Ahmed Glaucoma Valve and cyclophotocoagulation groups
P

AGV

CPC

Total

Number of Eyes

70

51

121

Number of Patients

70

51

121

Age: Years

66.0±15.0

68.4±15.3

67.0±15.1

0.390

Sex, Females n (%)

26 (37.1)

25 (49)

51 (42.1)

0.199

White

27 (38.6)

22 (43.1)

49 (40.5)

0.469

Black

26 (37.1)

12 (23.5)

38 (31.4)

Asian

3 (4.3)

2 (3.9)

5 (4.1)

Hispanic

5 (7.1)

4 (7.8)

9 (7.4)

Indian

1 (1.4)

0 (0.0)

1 (0.8)

Unknown

8 (11.4)

11 (21.6)

19 (15.7)

36 (51.4)

25 (49.0)

61 (50.4)

0.855

PDR

38 (54.3)

21 (41.2)

59 (48.8)

0.051

CRVO

23 (32.9)

15 (29.4)

38 (31.4)

CRAO

4 (5.7)

2 (3.9)

6 (5.0)

OIS

1 (1.4)

4 (7.8)

5 (4.1)

Combined

3 (4.3)

2 (3.9)

5 (4.1)

Others

1 (1.4)

7 (13.7)

8 (6.6)

Bilateral Retinal Pathology n (%)

38 (54.3)

19 (37.3)

57 (47.1)

0.069

Intravitreal Injection n (%)

54 (77.1)

16 (31.4)

70 (57.9)

<0.001

Panretinal Photocoagulation n (%)

52 (74.3)

6 (11.8)

58 (47.9)

<0.001

None

63 (90)

36 (70.6)

99 (81.8)

0.001

Prior Vitrectomy

4 (5.7)

1 (2.0)

5 (4.1)

Race n (%)

Surgical Eye, Right n (%)
NVG Etiology n (%)

Vitrectomy n (%)

Combined Vitrectomy

3 (4.3)

14 (27.5)

17 (14.0)

Visual Acuity: LogMAR

2.1±0.9

2.3±0.8

2.2±0.8

0.279

Intraocular Pressure: mm Hg

39.6±9.8

37.6±11.4

38.7±10.5

0.330

Medication Number

3.3±0.8

3.5±1.1

3.4±0.9

0.240

48 (68.6)
13 (18.6)

28 (54.9)
5 (9.8)

76 (62.8)
18 (14.9)

0.133
0.140

Synechial Angle Closure n (%)
Hyphema n (%)

AGV: Ahmed glaucoma valve. CPC: Cyclophotocoagulation. NVG: Neovascular glaucoma. PDR: Proliferative diabetic retinopathy. CRVO: Central retinal vein
occlusion. CRAO: Central retinal artery occlusion. OIS: Ocular ischemic syndrome. Bolded values denote statistical significance

Reasons for failure were comparable in both groups (P = 0.341).
Elevated IOP > 21 mm Hg (14 eyes or 41.2%) followed by
progression to NLP vision (10 eyes or 29.4%) were the most
common reasons for surgical failure. Failure due to more than
one reason (NLP, IOP >21 mm Hg, or glaucoma reoperation)
occurred in six (17.6%) eyes. Time to failure was also similar in
both groups (3.8 ± 1.8 vs. 3.8 ± 2.3 months, P = 0.941).
Visual acuity
The mean logMAR VA remained stable from baseline to
postoperative month 6 in the AGV group (2.1 ± 0.8 vs. 2.0 ± 1.0,
respectively; P = 0.114) and slightly deteriorated in the CPC
group (2.2 ± 0.9 vs. 2.4 ± 0.7, respectively; P = 0.076), although
this did not reach significance. Additionally, although
between‑group differences in baseline VA were not statistically
significant (P = 0.279), the CPC eyes had significantly lower
VA at 6 months compared to AGV eyes (2.4 ± 0.7 vs. 2.0 ± 1.0,
respectively; P = 0.005), and this difference remained
significant even after adjusting for baseline VA using analysis
of covariance testing (P = 0.009). Progression to NLP vision

at 6 months was higher in the CPC group (nine eyes or
17.6%) compared with the AGV group (four eyes or 5.7%),
but this difference was not statistically significant (P = 0.071).
Progression to NLP vision was similar in CW‑CPC and
MP‑CPC groups (P = 0.526).
Intraocular pressure
Both groups experienced signiﬁcant IOP reduction through
postoperative month 6. AGV eyes experienced a mean IOP
reduction from 39.8 ± 9.9 mm Hg at baseline to 16.3 ± 6.1 mm Hg
at month 6 (23.5 ± 10.1 mm Hg IOP reduction, P < 0.0001). CPC
eyes experienced a mean IOP reduction from 37.3 ± 11.9 mm Hg
at baseline to 16.2 ± 10.2 mm Hg at month 6 (21.1 ± 13.0 mm Hg
IOP reduction, P < 0.0001). The IOP difference between AGV and
CPC eyes at month 6 was not statistically signiﬁcant (P = 0.940)
and there was no significant difference between the CW‑CPC
and MP‑CPC groups (P = 0.451). However, the AGV eyes
had significantly lower IOP at the early postoperative period
(day 1 and week 1) compared with the CPC group (P < 0.001
for both) [Fig. 2a].
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Table 2: Month 6 outcomes of the Ahmed glaucoma valve and cyclophotocoagulation groups
AGV

CPC

Total

P

Visual Acuity: LogMAR

2.0±1.0

2.4±0.7

2.2±0.9

0.005

Intraocular Pressure: mm Hg

16.3±6.1

16.2±10.2

16.3±7.9

0.940

Medication Number

2.3±1.2

2.4±1.5

2.3±1.3

0.836

12 (17.1)

22 (43.1)

34 (28.1)

0.020

IOP >21 mm Hg

7 (58.3)

7 (31.8)

14 (41.2)

0.341

Progression to NLP

4 (33.3)

6 (27.3)

10 (29.4)

Glaucoma Reoperation

0 (0.0)

3 (16.3)

3 (8.8)

IOP <5 mm Hg

0 (0.0)

1 (4.5)

1 (2.9)

Combined

1 (8.3)

5 (22.7)

6 (17.6)

3.8±1.8

3.8±2.3

3.8±2.1

0.941

Hypotony

0 (0.0)

1 (2.0)

1 (0.8)

0.421

Suprachoroidal Hemorrhage

3 (4.3)

0 (0.0)

3 (2.5)

0.262

Tube Erosions

3 (4.3)
9 (17.6)
6 (11.8)

13 (10.7)
7 (5.8)

0.071
0.041

Surgical Failure n (%)
Reasons for Failure n (%)

Time to Failure: Months
Complication n (%)

Endophthalmitis
Progression to NLP n (%)
Glaucoma Reoperation n (%)

0 (0.0)
4 (5.7)
1 (1.4)

AGV: Ahmed glaucoma valve. CPC: Cyclophotocoagulation. IOP: Intraocular pressure. NLP: No light perception. Bolded values denote statistical significance

Table 3: Univariate and multivariate regression analyses of predictors for surgical failure at 6 months
Univariate

No Failure
n=87

Failure
n=34

Wald

P

Hazard
Ratio

95% Confidence
Interval

Age: Years

66.9±14.8

67.5±16.1

0.009

0.923

1.001

0.979‑1.024

Sex, Female n (%)

32 (36.8)

19 (55.9)

3.588

0.058

1.924

0.978‑3.789

White

34 (39.1)

15 (44.1)

0.512

0.474

0.889

0.644‑1.227

Black

26 (29.9)

12 (35.3)

40 (46)

19 (55.9)

0.157

0.692

0.953

0.75‑1.211

Race n (%)

NVG Etiology n (%)
PDR
CRVO
Bilateral Retinal Pathology n (%)

6 (6.9)

0 (0.0)

40 (46)

17 (50.0)

0.348

0.555

1.224

0.625‑2.398

1.2

0.273

0.724

0.406‑1.29

Vitrectomy n (%)
Prior Vitrectomy

4 (4.6)

1 (2.9)

14 (16.1)

3 (8.8)

Panretinal Photocoagulation n (%)

46 (52.9)

12 (35.3)

3.187

0.074

0.527

0.261‑1.065

Intravitreal Injection n (%)

53 (60.9)

17 (50)

1.347

0.246

0.672

0.343‑1.316

Preoperative IOP: mm Hg

36.9±10.0

43.8±10.3

9.123

0.003

1.054

1.019‑1.091

Preoperative Synechial Angle Closure n (%)

54 (62.1)

22 (64.7)

0.126

0.722

1.136

0.562‑2.296

Preoperative Hyphema n (%)
Surgery Type, CPC n (%)

15 (17.2)
29 (33.3)

3 (8.8)
22 (64.7)

1.316
8.143

0.251
0.004

0.500
1.669

0.153‑1.635
1.174‑2.372

Multivariate Model
P<0.001

No failure
n=87

Failure
n=34

Wald

P

Hazard
Ratio

95% Confidence
Interval

Preoperative IOP: mm Hg
Surgery Type, CPC n (%)

36.9±10.0
29 (33.3)

43.8±10.3
22 (64.7)

10.233
8.283

0.001
0.004

1.053
1.684

1.02‑1.087
1.181-2.401

Combined Vitrectomy

PDR: Proliferative diabetic retinopathy. CRVO: Central retinal vein occlusion. IOP: Intraocular pressure. CPC: Cyclophotocoagulation. Bolded values denote
statistical significance

Medical therapy
The need for medical therapy in both treatment groups was
significantly reduced through postoperative month 6. The mean

number of glaucoma medications in the AGV group decreased
from 3.3 ± 0.8 at baseline to 2.3 ± 1.2 at 6 months (1.0 ± 1.4
medication reduction, P < 0.0001). The mean number of
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Figure 1: Censored Kaplan–Meier survival analysis of surgical failure by treatment group

a

b

Figure 2: (a) Change in mean intraocular pressure in Ahmed glaucoma valve and cyclophotocoagulation treatment groups during the 6‑month
postoperative period. P values represent comparisons between the two treatment groups at each time point. (b) Change in the mean number of
glaucoma medications in Ahmed glaucoma valve and cyclophotocoagulation treatment groups during the 6‑month postoperative period. P values
represent comparisons between the two treatment groups at each time point

glaucoma medications in the CPC group decreased from
3.5 ± 1.1 at baseline to 2.4 ± 1.5 at 6 months (1.1 ± 1.7 medication
reduction, P < 0.0001). There was no significant difference
between the medication number in the two groups at month
6 (P = 0.836), and there was no significant difference between
the CW‑CPC and MP‑CPC groups (P = 0.323). However, the
AGV eyes needed a significantly lower number of medications
at all the visits prior to month 6 (P < 0.05 for all) [Fig. 2b].

AGV eyes and no CPC eyes (P = 0.262). Hypotony and
phthisis bulbi occurred in one (2.0%) CPC eye and no AGV
eyes (P = 0.421). In the AGV group, tube erosions requiring
revisions occurred in three (4.3%) eyes, but no eyes experienced
endophthalmitis at postoperative month 6. The total rate of
complication was higher in the AGV group (six eyes, 8.6%)
compared to the CPC group (one eye, 2.0%), but this difference
was not statistically significant (P = 0.236).

Postoperative complications
Serious postoperative complications were infrequent in both
groups. Suprachoroidal hemorrhage occurred in three (4.3%)

Reoperation for glaucoma
In total, seven (5.8%) eyes required reoperation for glaucoma
in the first 6 postoperative months, and the rate of reoperation
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was significantly higher in the CPC group (six eyes or 11.8%)
compared with the AGV group (one eye or 1.4%) (P = 0.041).
Among CPC eyes that required reoperation, two eyes were
in the CW‑CPC group and four eyes were in the MP‑CPC
group (P = 0.668). For all reoperated eyes, CPC was the
additional glaucoma intervention.

Discussion
Our retrospective study found that both AGV and CPC had
similar outcomes in terms of IOP and medication reduction in
NVG. Both procedures achieved more than 50% IOP reduction
and significantly less dependence on medications at month 6.
However, CPC was more frequently associated with surgical
failure, reoperation for glaucoma, and worse visual outcomes
as compared to AGV. High preoperative IOP and CPC surgery
were independent predictors of surgical failures. While other
studies have compared CPC and tube shunt surgery for NVG
treatment,[11,13] our study is the largest to do so. Although the
literature lacks a clear recommendation regarding the optimal
glaucoma surgery for the treatment of NVG, our study suggests
that AGV surgery may be associated with better outcomes as
compared to CPC.[14]
Limited studies have compared CPC and AGV implantation
for NVG.[11,13] In a prospective randomized pilot study, Yildirim
et al.[11] did not detect a difference in success between CPC
and AGV in the setting of NVG at 1 year (29% vs. 38.7%,
respectively; P > 0.05). Although our study used the same
failure criteria, we detected greater surgical success with
AGV as compared to CPC at postoperative month 6 (P = 0.02),
possibly because our study was better powered than that of
Yildirim et al. (121 vs. 58). Furthermore, treatment failures or
complications within the CPC group may be missed in the
Yildirim study as a greater proportion of CPC patients were
lost to follow‑up as compared to AGV patients. Similar to ours,
Yildrim et al. found that both procedures achieved significant
IOP and medication reduction as compared to baseline, and
there was no significant difference in the mean IOP between
groups at month 6 (P = 0.36). However, at month 1 in the
Yildirim study, the IOP was significantly lower in the AGV
group (P = 0.02), which is in agreement with our results.
Another pilot study of a substantially smaller group (N = 22)
compared AGV and CPC in NVG in a Chinese sample over an
average follow‑up duration of 30 months.[13] This prospective
randomized study reported that both AGV and CPC had a
similar success rate (86% for each group) by the final visit.
Of note, failure criteria in this study were based solely on
IOP, without considering progression to NLP or reoperation
for glaucoma as the study allowed CPC to be repeated up to
five times for IOP control. These differences and a potentially
inadequate sample size limit comparison with our study.
Eid et al.[12] compared the outcomes of tube shunts and
noncontact neodymium: YAG (Nd: YAG) CPC in NVG over
a mean follow‑up of 15 months. Similar to our findings, this
retrospective case‑matched study showed that the tube group
achieved significantly lower IOP in the early postoperative
period (week 1 and month 1). However, the mean IOP
became nearly equal in the two groups with time. Also,
the failure rate at the final visit was significantly higher in
the CPC group as compared to the tube group (P < 0.001).
Interestingly, the failure rate in this case series was much higher

Volume 70 Issue 4

in both groups as compared to our study (33.4% vs. 17.1%
for the tube group, and 79.2% vs. 43.1% for the CPC group).
Although progression to NLP was not counted as failure,
this higher failure rate may be attributed to longer follow‑up
duration (more than 1 year), inclusion of valved and non‑valved
tube shunts (AGV, Baerveldt implant, and Molteno implant),
different CPC types (noncontact Nd: YAG), and smaller sample
size (24 patients for each group).
Lima et al.[15] compared the 2‑year results of AGV and
endoscopic diode CPC in 68 eyes with refractory glaucoma,
in which NVG was the most common diagnosis in the
AGV (38.2%) and CPC (41.2%) groups. Unlike our study, they
reported a similar failure rate in both groups at 1 year (P = 0.1).
Similar to our findings, the IOP at month 6 and 12 was similar
between groups, but the AGV achieved better IOP in the first
week (P = 0.04).
In our multivariate model, high baseline IOP (P = 0.001) and
CPC surgery (P = 0.004) were independent predictors of surgical
failure, while age, sex, race, NVG etiology, bilaterality of the
underlying retinal pathology, perioperative PRP or intravitreal
anti‑VEGF, and prior or combined vitrectomy were not found to
be significant predictive factors. This was partially in agreement
with a prior study that did not identify an association between
PRP and anti‑VEGF therapy and long‑term IOP control.[16]
However, this study reported that synechial angle closure
had the greatest impact on final IOP, which was insignificant
in our study (P = 0.722). This discrepancy may be attributed
to the different design and surgical treatment in both studies
as they initially offered PRP with or without anti‑VEGF, and
trabeculectomy was only done if IOP was not controlled.[16] Our
study included patients who were treated with AGV or CPC
indicating advanced stages of NVG, and the majority of them
had synechial angle closure (62.8%). Similar to our study, a
meta‑analysis comparing the different NVG surgical treatments
reported that CPC was associated with a higher failure rate as
compared to tube shunts (P = 0.05), although both procedures
had similar IOP outcomes at month 6 (P = 0.16).[17]
NVG’s association with potential blindness is well‑known.[5,18]
Our study demonstrated that while both CPC and AGV groups
had similarly poor baseline VA (P = 0.279), CPC eyes
demonstrated significantly worse VA at month 6 (P = 0.017).
Interestingly, both groups experienced similar IOP reduction
at that time point (P = 0.854). These findings agree with
early studies on CPC, which demonstrated vision loss and
postoperative vision‑threatening complications.[19‑21] Of note,
our study showed a comparable rate of serious postoperative
complications in the CPC and AGV groups (P = 0.236).
Additionally, higher IOP was seen in the CPC group as
compared to the AGV group in the early postoperative period
in our studies and others.[11,12,15] This delayed effect on IOP may
be due to the mechanism of action of CPC, which is theorized as
coagulative necrosis of the secretory ciliary apparatus following
the absorption of laser energy.[21] Because IOP control is essential
to preserve the visual field in eyes with glaucoma,[22] this initially
higher IOP in CPC eyes might be responsible for VA worsening.
Our study has limitations. Being a retrospective study,
patient selection bias may have played a role. Although
baseline VA and IOP were similar between groups, CPC has
traditionally been used in eyes with poor visual prognosis,[21]
while AGV may have been chosen for healthier eyes with
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reversible causes of vision loss (e.g., corneal edema) rather than
irreversible optic neuropathy or ischemic retina. Moreover,
perioperative retina treatment including PRP and intravitreal
injection of anti‑VEGF was significantly lower in the CPC
group (P < 0.001 for both), which could have been a reason for
worsening vision in the CPC group due to retinal ischemia
rather than glaucoma.[1] The modest follow‑up duration of our
study (6 months) is another limitation. Furthermore, differences
in sample size in the AGV and CPC groups may have led to
inadequately powered analyses.

8.

Xie Z, Liu H, Du M, Zhu M, Tighe S, Chen X, et al. Efficacy of
Ahmed glaucoma valve implantation on neovascular glaucoma.
Int J Med Sci 2019;16:1371‑6.

9.

Kolomeyer AM, Seery CW, Emami‑Naeimi P, Zarbin MA,
Fechtner RD, Bhagat N. Combined pars plana vitrectomy and pars
plana Baerveldt tube placement in eyes with neovascular glaucoma.
Retina 2015;35:17‑28.

Conclusion

11. Yildirim N, Yalvac IS, Sahin A, Ozer A, Bozca T. A comparative
study between diode laser cyclophotocoagulation and the Ahmed
glaucoma valve implant in neovascular glaucoma: A long‑term
follow‑up. J Glaucoma 2009;18:192‑6.

Our results demonstrated that both AGV and CPC had
comparable IOP and medication reduction in NVG eyes
at postoperative month 6. CPC was associated with more
frequent surgical failure, reoperation for glaucoma, and worse
visual outcomes. High preoperative IOP and surgery type as
CPC were independent predictors of surgical failure. Future
randomized clinical trials on ideal surgical management in
NVG may be indicated.
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